RiVax is under clinical development by Soligenix and currently in Phase I for Poisoning. According to GlobalData, Phase I drugs for Poisoning have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how RiVax’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
RiVax overview
RiVax is under development to protect against exposure to ricin toxin poisoning. It is a lyophilized recombinant derivative of ricin A chain with aluminium hydroxide (Alum) adjuvanted formulation. Ricin is a dimeric cytotoxin produced and stored in the developing endosperm tissue of Ricinus communis seeds. The mature toxin is composed of an enzymatic ribosome-inactivating A chain (RTA) disulfide-bonded to a galactose-binding B chain (RTB). The drug candidate is a recombinant subunit vaccine that is developed based on ThermoVax technology.
Soligenix overview
Soligenix is a late-stage biopharmaceutical company which focuses on the development and commercialization of products for the treatment of rare diseases and unmet medical needs. It develops specialized biotherapeutics for the treatment of orphan diseases such as cutaneous T-cell lymphoma, pediatric Crohn’s disease, oral mucositis, mild to moderate psoriasis, and acute radiation enteritis. It develops proprietary formulations of oral beclomethasone 17,21-dipropionate (BDP) for the treatment of gastrointestinal disorders that are characterized by high inflammation. The company has active development programs for RiVax, a ricin toxin vaccine; and SGX943 for infectious disease. These vaccine programs are supported by ThermoVax, a heat stabilization technology. Soligenix is headquartered in Princeton, New Jersey, the US.
For a complete picture of RiVax’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
